Table 1.
Overall clinical features of cases included in the study
| Variable | Baseline distribution in cohort |
|---|---|
| Sample | |
| Sample size for sequencing | 418 |
| Sample size for outcome data | 418 |
| Median (range) follow-up | 5.4 (0.1–11.5) years |
| Demographics | |
| Sex | |
| Male | 243 (58.1%) |
| Female | 171 (40.9%) |
| NA | 4 (1%) |
| Age, mean ± SD | 56.6 ± 8.4 years |
| Biochemical | |
| β2 microglobulin, mean ± SD | 7.8 ± 9.6 (mg/L) |
| MM staging | |
| ISS I | 150 (35.9%) |
| ISS II | 102 (24.4%) |
| ISS III | 86 (20.6 %) |
| NA | 80 (19.1%) |
| Treatment | |
| VD-HDM | 266 (63.6%) |
| VTD-HDM | 53 (12.7%) |
| VAD-HDM | 67 (16.0%) |
| MPV/KMP | 5 (1.2%) |
| MPT | 10 (2.4%) |
| RD | 5 (1.2%) |
| SMM | 1 (0.2%) |
| NA | 11 (2.6%) |
| Outcome | |
| Relapse | 359/418 (85.9%) |
| Death | 202/418 (48.3%) |